<?xml version="1.0" encoding="utf-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005">
<channel xmlns:cfi="http://www.microsoft.com/schemas/rss/core/2005/internal" cfi:lastdownloaderror="None">
<title cf:type="text"><![CDATA[Editorial Board of Journal of Pharmaceutical Research -->Expert Forum]]></title>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[甘油的非临床安全性评价]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201308001&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2017/2/24 15:02:57</pubDate>
<category><![CDATA[Expert Forum]]></category>
<author><![CDATA[王庆利]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>王庆利</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201308001&flag=1]]></guid><cfi:id>45</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[药物基因组学与个体化治疗和药物临床评价]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201307001&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2017/2/24 15:03:36</pubDate>
<category><![CDATA[Expert Forum]]></category>
<author><![CDATA[郭建曼<sup>1,2</sup>,张蕊<sup>1</sup>,郭瑞臣<sup>1</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>郭建曼<sup>1,2</sup>,张蕊<sup>1</sup>,郭瑞臣<sup>1</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201307001&flag=1]]></guid><cfi:id>44</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[纳米药物递送系统在蛋白质药物中的应用]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201305001&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2017/2/24 15:24:13</pubDate>
<category><![CDATA[Expert Forum]]></category>
<author><![CDATA[曹锦花<sup>1</sup>,王凤山<sup>2</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>曹锦花<sup>1</sup>,王凤山<sup>2</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201305001&flag=1]]></guid><cfi:id>43</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[我国新修订GMP认证的现状、困境及对策研究]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201406001&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2017/2/23 10:18:17</pubDate>
<category><![CDATA[Expert Forum]]></category>
<author><![CDATA[颜建周,邵蓉]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>颜建周,邵蓉</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201406001&flag=1]]></guid><cfi:id>42</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[肿瘤靶向治疗药物载体的研究进展]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201405001&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2017/2/23 10:12:09</pubDate>
<category><![CDATA[Expert Forum]]></category>
<author><![CDATA[孙蕊,朱琰,刘玉琴]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>孙蕊,朱琰,刘玉琴</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201405001&flag=1]]></guid><cfi:id>41</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[近红外光谱分析技术在制药领域中的应用研究进展]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201403001&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2017/2/23 10:00:59</pubDate>
<category><![CDATA[Expert Forum]]></category>
<author><![CDATA[臧恒昌<sup>1</sup>,臧立轩<sup>1</sup>,张惠<sup>2</sup>,王金凤<sup>1</sup>,杨海龙<sup>1</sup>,姜玮<sup>1</sup>,柳东明<sup>1</sup>,王斐<sup>1</sup>,胡甜<sup>1</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>臧恒昌<sup>1</sup>,臧立轩<sup>1</sup>,张惠<sup>2</sup>,王金凤<sup>1</sup>,杨海龙<sup>1</sup>,姜玮<sup>1</sup>,柳东明<sup>1</sup>,王斐<sup>1</sup>,胡甜<sup>1</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201403001&flag=1]]></guid><cfi:id>40</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[脑胶质瘤治疗及其动物模型的研究进展]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201410001&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2017/1/11 14:59:11</pubDate>
<category><![CDATA[Expert Forum]]></category>
<author><![CDATA[仰浈臻,刘瑜洁,齐宪荣]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>仰浈臻,刘瑜洁,齐宪荣</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201410001&flag=1]]></guid><cfi:id>39</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[CD44介导的肿瘤靶向给药技术研究进展]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201502001&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2016/9/19 14:43:06</pubDate>
<category><![CDATA[Expert Forum]]></category>
<author><![CDATA[鞠安,田吉来,蒋雯,丁晨静,顾宁]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>鞠安,田吉来,蒋雯,丁晨静,顾宁</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201502001&flag=1]]></guid><cfi:id>38</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[A research and development overview of Fingolimod]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201512001&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Fingolimod (FTY720),a novel immunomodulator agent, is developed from ISP-1,which is a secondary metabolites of fungi.It was approved by FDA in 2012 for the treatment of autoimmune disease multiple sclerosis.Unlike the traditional immunosuppressive agents,fingolimod exerts immunosuppressive and immunoregulatory functions mainly through interaction with shhingosine-1-phosphate receptors (S1PR) on the cell surface without affecting activation and proliferation of lymphocyhtes.This article briefly reviewed the development process of fingolimod,elaborate the structural optimization and transformation,in order to provide experience for chemical rsearch.]]></description>
<pubDate>2016/3/29 9:07:18</pubDate>
<category><![CDATA[Expert Forum]]></category>
<author><![CDATA[NIU Jun-xing and HU Li-hong]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>NIU Jun-xing and HU Li-hong</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201512001&flag=1]]></guid><cfi:id>37</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Carfilzomib:from natural product to drug]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201510001&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Natural products and their derivatives have been invaluable as a source of therapeutic agents.Carfilzomib,a potential chemotherapy drug for patients with multiple myeloma, was developed from a microbial natural product Epoxomicin.Epoxomicin was found to exhibit potent anti-cancer activity,which might attribute to its inhibitory activity against proteasome. Because of its unique two-step binding mode, Epoxomicin has a clear advantage compared to other proteasome inhibitors with their substantial off-target activity.With a more pontecy and better drug-like properties,Carfilzomib was developed from the lead compound Epoxomicin and approved by FDA as a second-generation proteasome inhibitor in 2012.]]></description>
<pubDate>2016/5/9 14:57:57</pubDate>
<category><![CDATA[Expert Forum]]></category>
<author><![CDATA[NIU Jun-xing, XU Xing-yu and HU Li-hong]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>NIU Jun-xing, XU Xing-yu and HU Li-hong</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201510001&flag=1]]></guid><cfi:id>36</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[The solutions for supply problems in development of natural product-derived drugs]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201608001&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Natural products play a vital role in drug development as an important source of lead compounds. However, the amounts of biological active natural compounds, especially the complex entities, are usually deficient in nature for preclinical and clinical research. The problem of supply further restricts the development of the natural active products into market. This article briefly concludes four solutions for the problem of supply in order to provide experience for natural product-derived drugs development: (1) semi-synthesis from the abundant skeletons; (2) biomimetic synthesis from plentiful biosynthetic precursors; (3) chemical transformation from rich natural analogues; (4) full-synthesis after simplifying lead compounds.]]></description>
<pubDate>2016/8/8 10:12:08</pubDate>
<category><![CDATA[Expert Forum]]></category>
<author><![CDATA[XIAO Chengqian and HU Lihong]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>XIAO Chengqian and HU Lihong</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201608001&flag=1]]></guid><cfi:id>35</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[The principle and functions of RNA editing technology CRISPR/Cas9]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201601001&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Clustered regularly interspaced short palindromic repeat (CRISPR) and its associated protein(Cas) are essential components of nucleic-acid-based adaptive immune systems that are widespread in bacteria and archaea and have been developed as new targeted genome editing tools since the last two years. Because their flexible, efficient, cheap and easy to operate,they quickly surpass the previous technologies to become the hottest genome editing tools.In this review, we described the exciting breakthroughs in understanding the mechanism of the CRISPR systems (especially CRISPR/Cas9 system) and applications of Cas9 for a variety of research or translational applications.Derived from a remarkable microbial defense system,Cas9 was driving innovative applications from basic biology to biotechnology and medicine.]]></description>
<pubDate>2016/3/18 11:33:45</pubDate>
<category><![CDATA[Expert Forum]]></category>
<author><![CDATA[BAO Yong, JIANG Xiaoxiao and YANG Yonghua]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>BAO Yong, JIANG Xiaoxiao and YANG Yonghua</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201601001&flag=1]]></guid><cfi:id>34</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[An overview of structural modifications of amphotericin B]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201611001&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Amphotericin B has been the first choice of clinical drugs to treat systemic mycosis since it was launched on the market,which makes full use of its curative effects by selectively disrupting the cell membrane of fungi.But its clinical applications are greatly limited due to several drawbacks,such as poor solubility,low bioavailability,severe side effects,etc.Many scientists have devoted themselves to explore the mechanism of action and structural modification of amphotericin B over the years,and achieved significant results.This article briefly reviewed the progress in structural modification of amphotericin B,aiming at providing valuable information for related research.]]></description>
<pubDate>2016/11/9 9:59:02</pubDate>
<category><![CDATA[Expert Forum]]></category>
<author><![CDATA[LYU Xue and HU Lihong]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>LYU Xue and HU Lihong</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201611001&flag=1]]></guid><cfi:id>33</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[New Progress of Serum-and glucocorticoid-Inducible kinase 1 on CNS diseases]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201610001&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Serum-and glucocorticoid-Inducible kinase 1 (SGK1),a serine/threonine kinase,was discovered in rat mammary tumor cells which were stimulated by glucocorticoidin 1993.Unlike the case of most of protein kinases, SGK1 is not only regulated by post-translational phosphorylation/dephosphorylation,but also controled by the regulation mechanisms on rapid transcription.SGK1 has multiple physiological functions,such as participating in the regulation of ion channels,mediating the signal transduction of cell proliferation,differentiation,survival,and apoptosis.SGK1 is intimately associated with numerous central nervous system (CNS) diseases, including Parkinson's disease,Alzheimer's disease,and it plays an important role in the process of neuronal degeneration and apoptosis.This review introduced the structure and physiological functions of SGK1,elaborated the new progress of SGK1 on CNS diseases and the new development of its inhibitors.]]></description>
<pubDate>2016/10/12 14:45:15</pubDate>
<category><![CDATA[Expert Forum]]></category>
<author><![CDATA[CHEN Xiaoting<sup>1</sup>, CHEN Qiuhe<sup>1,2,3</sup>, TU Yalin<sup>1,2,3</sup> and PI Rongbiao<sup>1,2,3,4</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>CHEN Xiaoting<sup>1</sup>, CHEN Qiuhe<sup>1,2,3</sup>, TU Yalin<sup>1,2,3</sup> and PI Rongbiao<sup>1,2,3,4</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201610001&flag=1]]></guid><cfi:id>32</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Polymorphism of drugs:the main factor affecting the drug quality]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201706001&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[The quality of the small molecule drugs is an important and complex problems which related to clinical therapeutic effects.There are many different factors influencing the quality of drugs include API,excipients and preparation technology related factors.Except these factors,the crystal form of API is the core factors which closely related with bioavailability of drugs.Appliation and controlling the Optimal Drug Crystal form (ODC) of API in solid pharmaceutical preparations are the key procedures for drug quantity.This article discussed the discovery,detection,evaluation and application requirements of drug crystal,to provide information for the study of crysalline drugs.]]></description>
<pubDate>2017/6/19 13:58:14</pubDate>
<category><![CDATA[Expert Forum]]></category>
<author><![CDATA[DU Guanhua<sup>1</sup> and LYU Yang<sup>2</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>DU Guanhua<sup>1</sup> and LYU Yang<sup>2</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201706001&flag=1]]></guid><cfi:id>31</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Design strategy of anti-androgen targeting the non-HBP sites of androgen receptor]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201705001&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Androgen receptor (AR) is the most important target for the therapy of prostate cancer.However,the drug resistance during the treatment becomes the greatest challenge.Herein,we gave an overview of the structure and functions of AR and the drug resistances due to the mutations in the HBP site.Then this article summarized the design strategy of the AR antagonists targeting the non-HBP sites of AR,which should help to the development of novel anti-prostate cancer drugs.]]></description>
<pubDate>2017/5/23 16:01:08</pubDate>
<category><![CDATA[Expert Forum]]></category>
<author><![CDATA[LIU Yangguang, WU Meng, CEN Shan and ZHOU Jinming]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>LIU Yangguang, WU Meng, CEN Shan and ZHOU Jinming</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201705001&flag=1]]></guid><cfi:id>30</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[An overview in research and development process of a novel γ-secretase modulator SPI-1865]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201704001&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Alzheimer’s disease is a progressive neurodegenerative disorder,which is lack of efficient treatment measures.The β-amyloid (Aβ) oligomers and senile plaques,which are the result of β-amyloid aggregation outside the brain neurons,are strongly implicated the pathogenesis of AD.γ-Secretase,a key enzyme involved in generation of Aβ,is a potential target in the development of drugs for AD therapy.γ-Secretase modulators are highly selective and have broad application prospects.This article briefly reviewed the development process of a novel γ-Secretase modulator SPI-1865,aiming at providing valuable information for development and structural modifications of related GSM.]]></description>
<pubDate>2017/5/2 14:32:09</pubDate>
<category><![CDATA[Expert Forum]]></category>
<author><![CDATA[LYU Xue and HU Lihong]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>LYU Xue and HU Lihong</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201704001&flag=1]]></guid><cfi:id>29</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Advances in the research of tetracyclines antibiotics]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201701001&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Tetracyclines are broad spectrum antibiotics which can inhibit protein synthesis and are widely used against various bacterial infections.The extensive use of tetracyclines in animals and humans resulted in the emergence of widespread bacteria resistance which limited its application.So the further research to improve its properties is necessary.This article summarized the mechanism of antibacterial activity and bacterial drug resistance,structural modification and the structure-activity relationship,and the latest research progress on inhibiting tetracyclines resistant strains.]]></description>
<pubDate>2017/2/27 15:13:05</pubDate>
<category><![CDATA[Expert Forum]]></category>
<author><![CDATA[SUN Guanglong and HU Lihong]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>SUN Guanglong and HU Lihong</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201701001&flag=1]]></guid><cfi:id>28</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Biosynthesis of romidepsin-class anticancer drugs]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201712001&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Romidepsin (also known as FK228),a depsipeptide natural product biosynthesized by nonribosomal peptide synthases (NRPSs) and type I polyketide synthases (PKSs) in Chromobacteriumviolaceum, was identified as a potent histone deacetylase inhibitor (HDACi) and approved by the US FDA for the treatments of cutaneous T-cell lymphoma and peripheral T-cell lymphoma.In this paper,the progress regarding romidepsin-classnatural products identified in chemical structures,biosynthetic gene clusters and biosynthetic pathways werereviewed.The possibility of obtaining new romidepsin analogues via genome mining and combinatorial biosynthesis were also discussed.]]></description>
<pubDate>2018/1/4 15:58:18</pubDate>
<category><![CDATA[Expert Forum]]></category>
<author><![CDATA[TONG Tiantian, YUN Xuan<sup>1</sup>, CHENG Yiqiang<sup>1,2</sup>, DENG Zixin<sup>1</sup> and ZHU Dongqing<sup>1</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>TONG Tiantian, YUN Xuan<sup>1</sup>, CHENG Yiqiang<sup>1,2</sup>, DENG Zixin<sup>1</sup> and ZHU Dongqing<sup>1</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201712001&flag=1]]></guid><cfi:id>27</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Current status and development trend of oral iron supplement]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201711001&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Iron deficiency anemia (IDA) is the worldwide most prevalent nutritional deficiency disorder, which people have been dedicating to eradicating. IDA would affect body’s oxygen metabolism, energy metabolism, hematopoiesis and other life activities. Food fortification, oral iron supplement and parenteral iron supplement are mainly strategies to remedy IDA, among which oral iron supplement is the most widely applied in clinic due to cheap, easily absorb, high bioavailability and good compliance. In this article we introduced the study and application current states of traditional oral iron supplement summarily, discussed the issues which desiderate to be researched combined the research and development situations of novel oral iron supplement materials, and expected their development prospects.]]></description>
<pubDate>2017/12/7 15:02:26</pubDate>
<category><![CDATA[Expert Forum]]></category>
<author><![CDATA[MAO Yu, CHEN Bo and GU Ning]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>MAO Yu, CHEN Bo and GU Ning</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201711001&flag=1]]></guid><cfi:id>26</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Research advances on regulation of cytoskeleton function by natural bioactive constituents from traditional Chinese medicines]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201804001&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[The cytoskeleton is a dynamic network of intracellular protein fiber polymers, which participates in a variety of cellular activities, such as maintaining the internal structure of cells, stabilizing cell morphology, regulating cell division, endocytosis, exocytosis, information transfer and energy conversion.Cytoskeletal dysfunction has become a hallmark of many diseases such as neurological diseases, cardiovascular diseases and cancer. Studies have shown that active components from traditional Chinese medicines can regulate the cytoskeleton function of related diseases.This study focused on the mechanisms of active ingredients from traditional Chinese medicines regulating the cytoskeleton function of related diseases.The researches in recent 5 years were reviewed to illustrate the characteristic actions of active components from traditional Chinese medicine, and provide some references for treatment of related diseases.]]></description>
<pubDate>2018/5/23 17:07:54</pubDate>
<category><![CDATA[Expert Forum]]></category>
<author><![CDATA[HU Yang<sup>1,2</sup>, ZHANG Yuanyuan<sup>1,2</sup>, LI Fang<sup>1,2</sup>, WANG Jieman<sup>1,2</sup> and KOU Junping<sup>1,2</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>HU Yang<sup>1,2</sup>, ZHANG Yuanyuan<sup>1,2</sup>, LI Fang<sup>1,2</sup>, WANG Jieman<sup>1,2</sup> and KOU Junping<sup>1,2</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201804001&flag=1]]></guid><cfi:id>25</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Research progress on the safety and efficacy of Aconitum and its clinical application prospect]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201803001&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>Objective</b>  To analyze the research progress,application characteristics and precautions of aconite curative effect and safety in the literature,and to promote the clinical rationality and extensive application of this medicine and its compound preparation.<b>Methods</b>  The main literatures from the Qin and Han dynasties up to now were retrieved.The systemic summary and conclusion were given based on various aspects of the literatures,such as the pharmacological effects, the effective materials of the herb,processing types,pharmacokinetics in vivo,folk application,clinical efficacy and so on,and then the safe and effective application prospects and the basic requirements of the development of modern formulations were put forward.<b>Results</b>  The pharmacological effect of <i>Aconitum</i> is significant,with tumor suppressor,analgesia,improving immunity,anti-inflammatory and others.The size of its toxicity is aconitine, mesaconitine, hypaconitine>benzoyconaconitine,benzoylmesaconitine,benzoylhypaconitine>aconitine,mesaconine,hypaconine.In vivo studies showed that aconitine alkaloids absorbed very rapidly and metabolized rapidly in rats,but the data such as half-life in different literatures varied greatly,ranging from 0.936~20.130 hours for aconitine and 1.490~20.930 hours for mesaconitine,1.730~17.300 hours for hypaconitine.As a result,elimination rate in vivo and storage time are different significantly.Adverse reactions in clinical use mainly related with reasonable processing,proper compatibility,proper use,dosage control,avoiding the wrong service,individual difference and other misconducts.<b>Conclusion</b>  <i>Aconitum</i> application of solid foundation in folk,analgesic effect was good.The datum of processing technology,pharmacology and toxicology and clinical use were accurate,it was recommended to strengthen the confirmation of studies in vivo,to carry out clinical safety assessment to elucidate the mechanism of action and dose-response relationship.]]></description>
<pubDate>2018/4/19 15:28:04</pubDate>
<category><![CDATA[Expert Forum]]></category>
<author><![CDATA[YANG Miaomiao, YANG Lin and LI Xiaodong]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>YANG Miaomiao, YANG Lin and LI Xiaodong</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201803001&flag=1]]></guid><cfi:id>24</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Advance of sporadic Alzheimer's disease animal models]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201802001&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Alzheimer's disease (AD) is a central neurodegenerative disease，which is the most common type of dementia.Sporadic Alzheimer's disease is the main type of AD，and there is still no drug listed for the treatment. One of the key reasons may be the lack of animal model for sporadic Alzheimer's disease (sAD). Therefore，itis urgent and necessary to develop the sAD animal model.In this paper,we summarized the establishment，pathologic features and possible mechanisms of sAD animal model. In addition，the future direction for the development of sAD animal model were also discussed. We hope this review will be beneficial to the further researches of AD.]]></description>
<pubDate>2018/3/26 15:43:49</pubDate>
<category><![CDATA[Expert Forum]]></category>
<author><![CDATA[CHEN Chen<sup>1</sup>, WU Zeqing<sup>2</sup>, CHEN Qiuhe<sup>1</sup> and PI Rongbiao<sup>1,3,4</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>CHEN Chen<sup>1</sup>, WU Zeqing<sup>2</sup>, CHEN Qiuhe<sup>1</sup> and PI Rongbiao<sup>1,3,4</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201802001&flag=1]]></guid><cfi:id>23</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[树状大分子作为基因递送载体的研究进展]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201909001&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2019/10/10 16:10:16</pubDate>
<category><![CDATA[Expert Forum]]></category>
<author><![CDATA[胡正霞,何东升,涂家生]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>胡正霞,何东升,涂家生</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201909001&flag=1]]></guid><cfi:id>22</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Cellular temperature measurement and its application prospect in drug development]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201908001&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Cell is the basic unit of the structure and function of life. Measurement and analysis of cells can not only understand the physiological behavior of cells,but also help to explore the occurrence mechanism of related diseases. Temperature is the most important and fundamental parameter in cellular activities.The temperature of living cells changes during cell division, gene expression, enzyme reaction and other cellular activities. Therefore, measuring cellular temperature is crucial for a comprehensive understanding of the operation mechanism.With the development of micro-nano processing technology,cellular thermometers have been greatly improved in precision detection and micro-scale control. Here, current developments in cellular thermometers were highlighted, and a picture of their applications in drug development was presented.]]></description>
<pubDate>2019/8/30 17:59:12</pubDate>
<category><![CDATA[Expert Forum]]></category>
<author><![CDATA[HE Weinan, YAN Sen and GU Ning]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>HE Weinan, YAN Sen and GU Ning</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201908001&flag=1]]></guid><cfi:id>21</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Advances of active components of traditional Chinese medicines in the prevention and treatment of sepsis]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201906001&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Sepsis is a common critical disease in intensive care unit, also a dysregulated systemic inflammatory and immune response to microbial invasion that produces organ injury. Sepsis has a high mortality rate, which is a serious threat to human life. It’s a hot topic on development of new drug to treat sepsis in global. Many advances of active components from traditional Chinese medicines (TCMs) were reported in the treatment of sepsis in recent years. This article reviews the research progress of TCMs in the prevention and treatment of sepsis reported by foreign journals in the past three years, which includes five aspects such as inhibition of inflammatory reaction, inhibition of oxidative stress, regulation of immune response, regulation of cell death and endothelial barrier function etc, with an attempt to provide the theoretical basis for the development of new drugs for sepsis.]]></description>
<pubDate>2019/6/27 10:49:42</pubDate>
<category><![CDATA[Expert Forum]]></category>
<author><![CDATA[XUE Lixuan<sup>1,2</sup>, ZHOU Qianliu<sup>1,2</sup>, ZHANG Yuanyuan<sup>1,2</sup> and KOU Junping<sup>1,2</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>XUE Lixuan<sup>1,2</sup>, ZHOU Qianliu<sup>1,2</sup>, ZHANG Yuanyuan<sup>1,2</sup> and KOU Junping<sup>1,2</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201906001&flag=1]]></guid><cfi:id>20</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Research progress on TAF1 protein and its inhibitors]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201904001&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[The TAF1 (TATA-binding protein-associated factor 1) protein is a major component of the transcription factor IID which recognizes the acetylated lysine residue through its bromodomain and binds to the core promoter sequence to facilitate the transcription of target genes. This review introduces the structure of TAF1 protein and how it recognizes and binds to acetylated lysine markers. The related biology of TAF1 protein in gene transcription, cell proliferation, cell damage repair, and dystonia neurological diseases and tumors is discussed. The research progress of TAF1 (2) bromodomain inhibitors is also summarized.]]></description>
<pubDate>2019/5/10 16:54:53</pubDate>
<category><![CDATA[Expert Forum]]></category>
<author><![CDATA[CHEN Haifang, CHEN Yadong and TANG Weifang]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>CHEN Haifang, CHEN Yadong and TANG Weifang</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201904001&flag=1]]></guid><cfi:id>19</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Research progress of antiinfective drugs acting on bacterial aminoacyl-tRNA synthetase]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201903001&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Bacterial resistance has become a major threat to global public health, so the discovery of new antimicrobial agents has become an urgent task. As a key enzyme that catalyzes the binding of specific amino acids to tRNA, aminoacyl tRNA synthase plays an important role in protein synthesis. Due to the differences in the enzyme fine structure between eukaryotic and prokaryotic cells, it provides a structural basis for the design of inhibitors against bacterial aminoacyl tRNA synthase. In this paper, the structure, mechanism and classification of bacterial aminoacyl tRNA synthase were summarized, and the research status of anti-infective drugs aiming at this target was systematically discussed from the source of enzyme inhibitors.]]></description>
<pubDate>2019/4/12 10:55:29</pubDate>
<category><![CDATA[Expert Forum]]></category>
<author><![CDATA[ZHANG Shuo and LI Zhuorong]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>ZHANG Shuo and LI Zhuorong</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201903001&flag=1]]></guid><cfi:id>18</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Advances in anti-tumor effects of ursolic acid and its derivatives]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201902001&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Ursolic acid is a pentacyclic triterpenoid compound widely distributed in various medicinal plants such as Prunella vulgaris L. and Ligustrum lucidum, and has various biological activities.In vitro and in vivo studies have shown that ursolic acid has a broad anti-tumor spectrum and low toxicity to normal cells, and is an ideal natural anti-tumor drug candidate.It has a wider anti-tumor activity after structural modification.A comprehensive report on domestic and foreign literature reports on the anti-tumor effects of ursolic acid and its derivatives.]]></description>
<pubDate>2019/3/29 12:07:29</pubDate>
<category><![CDATA[Expert Forum]]></category>
<author><![CDATA[XIANG Runqing<sup>1</sup> and FAN Yuan<sup>2</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>XIANG Runqing<sup>1</sup> and FAN Yuan<sup>2</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201902001&flag=1]]></guid><cfi:id>17</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Targeting ferroptosis for cancer therapy]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202006001&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Ferroptosis is an iron-dependent form of regulated cell death caused by accumulation of lipid-based reactive oxygen species.The initiation and execution of ferroptosis lie at the intersection of iron homeostasis,lipid metabolism and antioxidant system.Based on the insight into the cross-talk between ferroptosis- and cancer-associated pathway, a series of ferroptosis-inducing agents have been designed and developed for cancer cells, including experimental compounds, clinical drugs and nanomaterials.This review summarized the regulatory mechanisms of ferroptosis and the strategies of cancer therapy based on ferroptosis.]]></description>
<pubDate>2020/7/3 13:44:29</pubDate>
<category><![CDATA[Expert Forum]]></category>
<author><![CDATA[QUAN Fei and YANG Yong]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>QUAN Fei and YANG Yong</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202006001&flag=1]]></guid><cfi:id>16</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[An overview of pharmacological actions of naringin and its aglycone naringenin on respiratory diseases]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202005001&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Naringin and its aglycone naringenin are common dihydroflavonoids existed in various plants and Chinese herbal medicines. Both compounds are found to possess a wide range of biological activities, including anti-inflammatory, anti-oxidation, improving metabolic syndrome, neuroprotection, anti-hepatic injury, anti-osteoporosis, etc. In recent years, the pharmacological effects of naringin and naringenin in respiratory diseases have received much attention. Our group have systematically investigated the therapeutic efficacies of naringin and naringenin on antitussive, expectorant, anti-pulmonary inflammation, and further developed naringin into a national first-class drug. At present, Phase I clinical trial of naringin has been completed. This article attempts to summarize the research progress of pharmacological effects of naringin and naringenin in respiratory diseases, including antitussive, expectorant, anti-pulmonary inflammation and anti-pulmonary fibrosis, with a view to provide reference for related research and clinical application.]]></description>
<pubDate>2020/5/28 11:25:44</pubDate>
<category><![CDATA[Expert Forum]]></category>
<author><![CDATA[LI Peibo, WANG Yonggang, WU Hao, SHI Rui, PENG Wei and SU Weiwei]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>LI Peibo, WANG Yonggang, WU Hao, SHI Rui, PENG Wei and SU Weiwei</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202005001&flag=1]]></guid><cfi:id>15</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[抗疟药氯喹：抗病毒的重磅武器？]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202002001&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2020/3/30 14:28:09</pubDate>
<category><![CDATA[Expert Forum]]></category>
<author><![CDATA[陈晨<sup>1</sup>,朱泽宇<sup>1</sup>,彭伟嘉<sup>1</sup>,杨扬<sup>1</sup>,鲁俊锋<sup>1</sup>,刘宇洁<sup>2</sup>,皮荣标<sup>3,4</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>陈晨<sup>1</sup>,朱泽宇<sup>1</sup>,彭伟嘉<sup>1</sup>,杨扬<sup>1</sup>,鲁俊锋<sup>1</sup>,刘宇洁<sup>2</sup>,皮荣标<sup>3,4</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202002001&flag=1]]></guid><cfi:id>14</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[卡托普利：从多肽到小分子降血压药物的研发历程]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202001001&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2020/3/10 15:53:26</pubDate>
<category><![CDATA[Expert Forum]]></category>
<author><![CDATA[文雨,刘健,胡立宏]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>文雨,刘健,胡立宏</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202001001&flag=1]]></guid><cfi:id>13</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[The Therapeutic Substances and Pharmacological Mechanism of <i>Corydalis saxicola</i> Bunting Total Alkaloids]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202107001&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<i>Corydalis saxicola</i> Bunting (CSB) is a traditional folk Chinese medicine with wide effects including clearing away heat, detoxifying, relieving pain and stopping bleeding and so on. So far, the research on pharmacological effects and mechanism of <i>Corydalis saxicola</i> Bunting mainly involves hepatoprotective, analgesic, anti-tumor, antibacterial effects, etc. The main chemical components of <i>Corydalis saxicola</i> Bunting with pharmacological effects are alkaloids, which are called <i>Corydalis saxicola</i> Bunting total alkaloids (CSBTA). However, there are few studies on the therapeutic substances in CSBTA. This review highlights the studies of CSBTA on therapeutic substances, pharmacological effects and mechanism, aiming to provide reference for its rational clinical use and further development based on the new dosage form and new indications.]]></description>
<pubDate>2021/8/16 15:40:08</pubDate>
<category><![CDATA[Expert Forum]]></category>
<author><![CDATA[GUO Yating<sup>1</sup>, SUN Qiushuang<sup>1</sup>, QIU Zhixia<sup>2</sup>, HUANG Fang<sup>1</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>GUO Yating<sup>1</sup>, SUN Qiushuang<sup>1</sup>, QIU Zhixia<sup>2</sup>, HUANG Fang<sup>1</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202107001&flag=1]]></guid><cfi:id>12</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[新型抗前列腺癌药物ODM-201的研究进展]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202106001&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2021/7/22 14:32:18</pubDate>
<category><![CDATA[Expert Forum]]></category>
<author><![CDATA[黄晨超，包旗旗，张荣玉，周金明]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>黄晨超，包旗旗，张荣玉，周金明</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202106001&flag=1]]></guid><cfi:id>11</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[The key problem of TCM consistency evaluation-Both Determination and assessing method of <i>in vitro</i> dissolution for TCM solid preparations]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202105001&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[With the modernization development of Traditional Chinese medicine (TCM) preparations, in vitro dissolution has been widely recognized as an important indicator for the technology control of solid preparations. In allusion to the complex diversity of TCM efficacy components, this paper reviewed the literatures to strenthen on the significances of the dissolution determination,dissolution determination devices, detection methods and data processing methods based on the literatures.The Macro Qualitative Similarity <i>S</i><sub>m</sub>≥0.9 and Macro Quantitative Similarity 70%≤<i>P</i><sub>m</sub>≤110% of the dissolution curve points for the different solid preparations from batche to batche serve as the new standards to determine the consistency of the dissolution curve proposed，which provide the new control criteria for the dissolution test of TCM solid preparations.The consistency of in vitro dissolution is the prerequisite for evaluating both whether theconsistency technology of TCM solid preparations is constant specification and whether the efficacy is optimal. It’s not difficult to control the total amount of pharmacodynamic substances in the consistency control of TCM, but the most difficult is to control the consistency of the dissolution of TCM solid preparations.Dissolution control. Therefore obviously the key and most difficult point in TCM consistency control is TCM solid preparations consistency control.]]></description>
<pubDate>2021/6/23 9:41:40</pubDate>
<category><![CDATA[Expert Forum]]></category>
<author><![CDATA[ZHANG Qinyi<sup>1</sup>, SHEN Guoxiang<sup>2</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>ZHANG Qinyi<sup>1</sup>, SHEN Guoxiang<sup>2</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202105001&flag=1]]></guid><cfi:id>10</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Research progress on new suppositories]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202104001&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[As a traditional semi-solid preparation, suppository can work in local cavity or whole body. In recent years, with the continuous development of preparation technology, researchers have developed a variety of new suppositories. Among them, hollow suppositories have the characteristics of rapid drug release by filling the hollow part of the drug; double-layer suppositories can be loaded with two drugs at the same time. The controlled release of drugs can be achieved through different layers of different matrices; in addition, there are a variety of sustained and controlled release suppositories such as microcapsule type, matrix type, gel type, osmotic pump type and so on. These new suppositories have shown good application prospects in personalized drug delivery. This article will review the preparation methods and characteristics of the above new suppositories.]]></description>
<pubDate>2021/5/25 19:40:51</pubDate>
<category><![CDATA[Expert Forum]]></category>
<author><![CDATA[CHENG Huiling<sup>1</sup>, TONG Qirong<sup>1</sup>, XIAO Yao<sup>2</sup>, HE Shuwang<sup>2</sup>, ZHAI Guangxi<sup>1</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>CHENG Huiling<sup>1</sup>, TONG Qirong<sup>1</sup>, XIAO Yao<sup>2</sup>, HE Shuwang<sup>2</sup>, ZHAI Guangxi<sup>1</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202104001&flag=1]]></guid><cfi:id>9</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Advance of Large-scale Alzheimer’s Disease Animal Models]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202207001&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Alzheimer’s disease (AD) is a complex neurodegenerative disease that mostly occurs in the elderly and can lead to cognitive impairment. At present, taking small animals as research models has some limitations in AD mechanism research and drug development, and there is an urgent need to develop more effective models. The genome and brain structure and function of large animals such as pigs, dogs and non-human primates are very similar to human beings. They are considered to be ideal animals for developing effective disease models. This paper summarized the pathological characteristics of pigs, dogs and non-human primates AD model animals, analyzed some advantages and disadvantages of AD large animal models, and discussed the development trend of AD animals in the future.]]></description>
<pubDate>2022/8/3 16:00:54</pubDate>
<category><![CDATA[Expert Forum]]></category>
<author><![CDATA[ZHONG Weicong<sup>1</sup>, ZHANG Ran<sup>2</sup>, PI Rongbiao<sup>1</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>ZHONG Weicong<sup>1</sup>, ZHANG Ran<sup>2</sup>, PI Rongbiao<sup>1</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202207001&flag=1]]></guid><cfi:id>8</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Research progress of cyclodextrin inclusion complexes for injection]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202305001&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[In order to improve the solubility of poorly water-soluble drugs, the solubilization methods used in conventional injections are mostly the addition of organic cosolvents or surfactants, whose irritation may lead to several adverse effects such as pain and inflammation. Cyclodextrin（CD） is a type of cyclic oligosaccharide with cavity. Partial natural cyclodextrins and their derivatives are water-soluble and biocompatible, making them a more preferable choice of solubilizer in injectable agents. They can increase the solubility and stability of drugs by forming inclusion complexes and the irritation to the injection site can be reduced. This review summarized the application and development prospects of marketed injections with cyclodextrins , and provide references on the wider application of cyclodextrin in injectable products.]]></description>
<pubDate>2023/6/26 13:41:40</pubDate>
<category><![CDATA[Expert Forum]]></category>
<author><![CDATA[YAN Jiarui<sup>1</sup>, YAN Zhen<sup>2</sup>, YIN Lifang<sup>1,2</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>YAN Jiarui<sup>1</sup>, YAN Zhen<sup>2</sup>, YIN Lifang<sup>1,2</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202305001&flag=1]]></guid><cfi:id>7</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Recent development of hydrogel based nucleic acids loading strategies]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202304001&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Gene therapy has broad application prospects in the treatment of cancer and genetic diseases. The key of gene therapy is how to accurately deliver nucleic acid drugs to the target site. In recent years, researchers are committed to loading nucleic acid drugs into hydrogels to achieve systemic or localized gene delivery. Hydrogel system provides an effective tool for the delivery of nucleic acid due to its good biocompatibility, efficient nucleic acid loading capacity and localized controlled release, and has great potential in the field of solid tumors and regenerative medicine. In this review, we summarized the recent studies on the hydrogel system as a nucleic acid carrier, and focused on the nucleic acid loading strategy based on hydrogel, to provide a reference for the research on the nucleic acid delivery system based on hydrogel.]]></description>
<pubDate>2023/5/31 10:08:13</pubDate>
<category><![CDATA[Expert Forum]]></category>
<author><![CDATA[LI Chenghao<sup>1,2</sup>, HE Dongsheng<sup>1,2</sup>, TU Jiasheng<sup>1,2</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>LI Chenghao<sup>1,2</sup>, HE Dongsheng<sup>1,2</sup>, TU Jiasheng<sup>1,2</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202304001&flag=1]]></guid><cfi:id>6</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Research advances on chemicals, bioactivities and quality control of medical plants from <i>Myricaria</i>]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202302001&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[The twigs and leaves of <i>Myricaria</i> plants (Tamaricaceae) have been traditionally used as <i>Shuibaizhi</i> in Tibet and Inner Mongolia for the treatment of rubella and rheumatoid arthritis in clinic. However, the lack of research on the chemical constituents, effective components and pharmacological mechanisms of <i>Myricaria</i> plants led to the difficulty in controlling the quality of <i>shuibaizhi</i>, and further blocked the application and development of the drug. Herein, the chemical compounds and biological activities of seven major <i>Myricaria</i> plants were reviewed, as well as the quality standards of shuibaizhi, aiming to provide a reference for the research in depth.]]></description>
<pubDate>2023/4/21 10:23:01</pubDate>
<category><![CDATA[Expert Forum]]></category>
<author><![CDATA[ZHANG Mengyao<sup>1</sup>, DE Ji<sup>2</sup>, CHEN Daofeng<sup>1</sup>, LU Yan<sup>1</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>ZHANG Mengyao<sup>1</sup>, DE Ji<sup>2</sup>, CHEN Daofeng<sup>1</sup>, LU Yan<sup>1</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202302001&flag=1]]></guid><cfi:id>5</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[The quality control policy for classical prescriptions-the consistency control technology based on both "theory of same quantity to same effect" and the quantitative fingerprints]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202301001&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Classical prescriptions have been handed down for hundred years in Chinese history, and their clinical trials are well established and their safety and efficacy are well tested. Classical prescriptions have been one of the most popular research topics in recent years, and there is a growing body of literature reporting on research related to it. However, due to their long history, there are errors in their drug base origin, concoction methods and dose conversions from the current standards, making the research process and quality control methods of classical famous prescriptions particularly important. This paper reviews on the four main aspects of classical prescriptions, including research objectives and core essence, research values, research processes and quality control strategies and methods.In this paper, we systematically propose that the essence of classical prescriptions - based on both "theory of same quantity to same effect" and quantitative fingerprint in consistency control strategies - should be studied and controlled in depth for standard decoction, control preparations, standard preparations, substance benchmarks, benchmark samples and quality standards, as well as the meaning of quantitative transfer, in order to find the deep connotation and quantitative value of these concepts. The concept of "standard decoction, control preparation, standard formulation, substance reference, reference sample and quality standard, as well as the meaning of quality value transmitting, are investigated and controlled to find the deep connotation and quantitative correlation of these concepts. The final quality standard for the standard formulation is determined on the basis of the substance benchmark, in which the a.<i>S</i><sub>m</sub>≥0.90;b.80%≤<i>P</i><sub>m</sub>≤120% is achieved according to quantitative fingerprinting checks to control quality consistency.]]></description>
<pubDate>2023/2/27 10:11:22</pubDate>
<category><![CDATA[Expert Forum]]></category>
<author><![CDATA[WANG Xinyi<sup>1</sup>, SUN Guoxiang<sup>1</sup>, SUN Wanyang<sup>2</sup>, LAN Lili<sup>1</sup>, YANG Ting<sup>1</sup>, XIAO Wanzhen<sup>1</sup>, YANG Huizhi<sup>1</sup>, HE Rongrong<sup>2</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>WANG Xinyi<sup>1</sup>, SUN Guoxiang<sup>1</sup>, SUN Wanyang<sup>2</sup>, LAN Lili<sup>1</sup>, YANG Ting<sup>1</sup>, XIAO Wanzhen<sup>1</sup>, YANG Huizhi<sup>1</sup>, HE Rongrong<sup>2</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202301001&flag=1]]></guid><cfi:id>4</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Research progress on tumor in situ vaccines]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202406001&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Tumor vaccine is considered to be a promising immunotherapy method for tumors, but the high heterogeneity and mutation rate of tumors themselves greatly limit the development of traditional tumor vaccines. Compared with the traditional tumor vaccine, the tumor in situ vaccine can directly transform the tumor lesion itself into an "antigen factory", which has many advantages such as low systemic toxicity, high bioavailability, strong personalized degree, low time and economic cost, and has great therapeutic potential and clinical transformation value. It can induce local immunogenic cell death in tumors, promote the release of tumor antigens and immune-activating mediators, initiate or restart the "tumor-immune cycle" that has been silenced in the body, and further induce tumor-specific immune memory. This paper focuses on tumor in situ vaccine, introduces in detail its anti-tumor mechanism and specific strategies with key clinical results, reveals the application potential and challenges of tumor in situ vaccine, and provides theoretical references for the design of tumor in situ vaccine.]]></description>
<pubDate>2024/7/22 17:21:22</pubDate>
<category><![CDATA[Expert Forum]]></category>
<author><![CDATA[ZUO Luoyi, YANG Yong]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>ZUO Luoyi, YANG Yong</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202406001&flag=1]]></guid><cfi:id>3</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Process and application of ECD calculation in determining the absolute configuration of natural molecules]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202507001&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[It is of great significance to determine the absolute configuration of chiral compounds accurately and effectively in drug research and development. Electron circular dichroism (ECD) calculation has become a general method to determine the absolute configuration of chiral compounds, by comparing the experimental ECD spectra with those calculated theoretically, researchers can quickly determine the absolute configuration of small organic molecules. The knowledge required to perform ECD calculations involves many disciplines such as computation, mathematics, spectroscopy, etc. In addition, the choice of calculation method, base group and solvation model will affect the accuracy of ECD calculation. Based on this, this review synthesizes the basic principle of computing ECD, the general process, the selection of theoretical level, the calculation examples, and the solution of common problems in computing, aiming at enabling experimental chemists to understand the necessary knowledge required for computing ECD and quickly carry out theoretical research on computing ECD.]]></description>
<pubDate>2025/8/8 8:41:34</pubDate>
<category><![CDATA[Expert Forum]]></category>
<author><![CDATA[XI Zihan, LYU Tianming, LOU Lili, HUANG Xiaoxiao]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>XI Zihan, LYU Tianming, LOU Lili, HUANG Xiaoxiao</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202507001&flag=1]]></guid><cfi:id>2</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Research progress in AI-enabled diagnosis and treatment of glioma]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202504001&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Glioma is the main tumor type in the central nervous system and also the most common primary intracranial malignant tumor.Its diagnosis and treatment have always been major challenges in the medical field. In recent years， the rapid development of artificial intelligence has brought new opportunities for the diagnosis,treatment and prognosis of glioma. This review summarizes the current application status of AI in the diagnosis,treatment and prognosis of glioma， and analyzes the current opportunities and challenges,aiming to provide a reference for the further applications of AI in the diagnosis and treatment of glioma.]]></description>
<pubDate>2025/5/9 9:16:54</pubDate>
<category><![CDATA[Expert Forum]]></category>
<author><![CDATA[YE Gongyan<sup>1</sup>, JI Min<sup>2</sup>, LI Yingjie<sup>2</sup>, HUANG Rongqin<sup>1</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>YE Gongyan<sup>1</sup>, JI Min<sup>2</sup>, LI Yingjie<sup>2</sup>, HUANG Rongqin<sup>1</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202504001&flag=1]]></guid><cfi:id>1</cfi:id><cfi:read>true</cfi:read></item>
</channel>
</rss>